Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine hydrochloride + bacitracin zinc + neomycin sulfate + polymyxin b is an over-the-counter topical combination small-molecule drug product that combines a local anesthetic with three topical antibiotics for first-aid use on minor cuts, scrapes, and burns. Lidocaine hydrochloride provides temporary pain relief by blocking voltage-gated sodium channels in peripheral nerves, while bacitracin zinc inhibits bacterial cell wall synthesis, neomycin sulfate inhibits bacterial protein synthesis by binding the 30S ribosomal subunit, and polymyxin b disrupts the bacterial cell membrane, particularly in susceptible Gram-negative organisms. The product is marketed in ointment and cream presentations under brand names such as Neosporin Plus and related store-brand equivalents; the provided context also links the combination name to painful urethritis, but that urethritis indication more classically corresponds to lidocaine hydrochloride jelly rather than the topical four-component first-aid antibiotic combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine hydrochloride + bacitracin zinc + neomycin sulfate + polymyxin b.